Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels. (21st October 2018)

• Record Type: Journal Article
• Authors: Ju, Rui-Jun; Cheng, Lan; Qiu, Xiao; Liu, Shuang; Song, Xiao-Li; Peng, Xiao-Ming; Wang, Teng; Li, Cui-Qing; Li, Xue-Tao
• Is Part Of: Journal of drug targeting. Volume 26:Number 9(2018)
• Page Start: 793
• Page End: 805
• Publication Date: 2018-10-21
• Subjects: Daunorubicin -- honokiol -- hyaluronic acid -- vasculogenic mimicry -- cationic liposomes; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2018.1428809
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Background: Breast cancer is an alarming global public health problem and a main cause of cancer-related death in women. Systemic chemotherapy is the most widely used treatment for breast cancer. However, current chemotherapy treatments are far from desirable due to poor targeting specificity, severe side effects and vasculogenic mimicry (VM). Purpose: Hyaluronic acid (HA)-modified daunorubicin plus honokiol (HNK) cationic liposomes were prepared and characterised for treatment of breast cancer by eliminating VM. Methods: HA-modified daunorubicin plus HNK cationic liposomes were prepared by a thin-film hydration method. Evaluations were performed on MCF-7 cells and MDA-MB-435S cells, which are human breast cancer cells, and xenografts of MDA-MB-435S cells. Results: In vitro results revealed that the HA-modified daunorubicin plus HNK cationic liposomes enhanced the cellular uptake and destroyed VM channels. In vivo results demonstrated that the liposomes prolonged the circulation time in the blood, obviously accumulated in the tumour region, and enhanced the overall anticancer effects. Action mechanisms were related to down-regulation of VM protein indicators including FAK, EphA2, MMP-2 and MMP-9. Conclusions: The prepared HA-modified daunorubicin plus HNK cationic liposomes may serve as a promising therapeutic strategy for the treatment of breast cancer.